Stemirna’s mRNA cancer vaccine trial on hold, reports say

27 March 2024
china_shanghai_big

Chinese mRNA company Stemirna Therapeutics has halted an early-stage trial of a cancer vaccine, according to a Reuters report.

Researchers working on the trial have been quoted in the report as saying that the trial of the Shanghai-based company’s vaccine SW1115C3, in malignant solid tumors, has been on hold for several months.

This latest setback follows reports in December that Stemirna had been unable to make wage payments to staff and was struggling to raise fresh financing. Chinese media have also reported on the company’s debts and legal woes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology